The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet.
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the Western population. By mechanisms that are not completely understood, this disease may progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). db/db mice spontaneously develop hepatic steatosis, which progresses to NASH when these mice are fed a methionine choline-deficient (MCD) diet. The goal of our studies was to identify lipid and methionine metabolism pathways affected by MCD feeding to determine potential causal events leading to the development of NASH from benign steatosis. db/db mice fed the MCD diet for 2 weeks exhibited signs of incipient NASH development such as upregulated cytokines and chemokines. At this time point, MCD diet feeding caused S-adenosylmethionine (SAMe) depletion in db/db mice, while wild-type mice on the same diet retained hepatic SAMe levels. SAMe depletion exerts pleiotropic effects upon liver homeostasis and is commonly associated with a variety of liver insults such as thioacetamide, CCL4, and alcohol treatment; thus, SAMe depletion may serve as the second hit in NASH development. It is possible that differences in hepatic lipid and/or methionine metabolism between wild-type and db/db mice underlay the differential maintenance of SAMe levels during methionine and choline restriction. Indeed, db/db mice exhibited inhibited lipid oxidation pathways, which may be a priming factor for NASH development, and db/db mice fed the MCD diet had differential methionine adenosyltransferase (MAT) expression. The occurrence of SAMe depletion at this early, benign stage of NASH development in db/db mice with fatty liver suggests that SAMe supplementation may be (A) targeted to individuals susceptible to NASH (i.e., NAFLD patients) and (B) preventative of NASH before substantial liver injury has occurred.
Wortham
Matthew
M
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
He
Lin
L
Gyamfi
Maxwell
M
Copple
Bryan L
BL
Wan
Yu-Jui Yvonne
YJ
D000818:Animals; D002794:Choline / Q000008:administration & dosage / Q000378:metabolism*; D004195:Disease Models, Animal; D018450:Disease Progression; D005234:Fatty Liver / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005526:Food, Formulated; D005978:Glutathione / Q000378:metabolism; D006505:Hepatitis / Q000378:metabolism* / Q000473:pathology; D006706:Homeostasis; D050356:Lipid Metabolism / Q000502:physiology; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008715:Methionine / Q000008:administration & dosage / Q000378:metabolism*; D051379:Mice; D008817:Mice, Mutant Strains; D008820:Mice, Obese; D009765:Obesity / Q000378:metabolism* / Q000473:pathology; D012436:S-Adenosylmethionine / Q000378:metabolism*
D012436:S-Adenosylmethionine; D008715:Methionine; D005978:Glutathione; D002794:Choline